The transcription factor c-Myc is amplified/upregulated in several sarcomas with complex genetics including leiomyosarcoma, osteosarcoma, liposarcoma, chondrosarcoma and rhabdomyosarcoma, and this has been associated with cancer aggressiveness and poor clinical outcome (1, 5–11). This evidence concerns the gene MYC and rhabdomyosarcoma.